View More Recent Stories
-
B.Riley Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) no longer intends to offers ordinary shares
-
After-hours movers: KB Home, Progress Software, Worthington Industries and more
-
WAVE Life Sciences (WVE) Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
-
WAVE Life Sciences (WVE) PT Raised to $22 at H.C. Wainwright
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Announces Positive Interim Data from FORWARD-53 Trial of WVE-N531
-
UBS Starts LEM Holding SA (LEHN:SW) at Buy
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
-
Jones Trading Starts WAVE Life Sciences (WVE) at Buy
-
WAVE Life Sciences (WVE) Misses Q2 EPS by 4c
-
Truist Securities Defending WAVE Life Sciences (WVE): 'We're Buyers Of Weakness Today'
-
WAVE Life Sciences (WVE) Announces Positive Results from Phase 1b/2a SELECT-HD Trial
